利用长期随访队列验证两种IgA肾病风险预测工具
研究纳入306例经活检证实的原发性IgA肾病患者,中位随访17.1年,外部验证国际IgA肾病预测工具与IgA肾病临床决策支持系统。国际IgA肾病预测工具区分度与校准良好,IgA肾病临床决策支持系统在高风险患者中低估风险、低风险类别中高估风险。
要点
- 国际IgA肾病预测工具在5年时AUC为0.90,20年时AUC为0.83,校准良好。
- IgA肾病临床决策支持系统时间朴素分析AUC为0.83,但校准存在局限。
- IgA肾病临床决策支持系统对高风险患者低估风险,对低风险类别高估风险。
核心结论
- 外部验证了两种IgA肾病预测工具,国际IgA肾病预测工具表现良好,而IgA肾病临床决策支持系统存在一些局限性。
研究设计与样本
- 研究纳入306例经活检证实的原发性IgA肾病患者,组织病理样本取自挪威肾脏活检登记处并按牛津分类重新分类,采用区分度和校准原则进行外部验证。
主要发现
- 中位患者随访时间为17.1年。
- 累积动态时间依赖受试者工作特征分析显示,国际IgA肾病预测工具的曲线下面积值从5年时的0.90到20年时的0.83。
- 时间朴素分析显示,IgA肾病临床决策支持系统的曲线下面积值为0.83。
- 国际IgA肾病预测工具校准良好,而IgA肾病临床决策支持系统倾向于对较高风险患者低估风险,对较低风险类别高估风险。
临床怎么用
- 原文未据此给出推荐。
局限性
- IgA肾病临床决策支持系统存在一些局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recently, two immunoglobulin A (IgA) nephropathy-prediction tools were developed that combine clinical and histopathologic parameters. The International IgAN Prediction Tool predicts the risk for 50% declines in the estimated glomerular filtration rate or end-stage kidney disease up to 80 months after diagnosis. The IgA Nephropathy Clinical Decision Support System uses artificial neural networks to estimate the risk for end-stage kidney disease. We aimed to externally validate both prediction tools using a Norwegian cohort with a long-term follow-up. METHODS: We included 306 patients with biopsy-proven primary IgA nephropathy in this study. Histopathologic samples were retrieved from the Norwegian Kidney Biopsy Registry and reclassified according to the Oxford Classification. We used discrimination and calibration as principles for externally validating the prognostic models. RESULTS: The median patient follow-up was 17.1 years. A cumulative, dynamic, time-dependent receiver operating characteristic analysis showed area under the curve values ranging from 0.90 at 5 years to 0.83 at 20 years for the International IgAN Prediction Tool, while time-naive analysis showed an area under the curve value at 0.83 for the IgA Nephropathy Clinical Decision Support System. The International IgAN Prediction Tool was well calibrated, while the IgA Nephropathy Clinical Decision Support System tends to underestimate risk for patients at higher risk and overestimates risk in the lower risk categories. CONCLUSIONS: We have externally validated two prediction tools for IgA nephropathy. The International IgAN Prediction Tool performed well, while the IgA Nephropathy Clinical Decision Support System has some limitations.
引用
- Haaskjold YL, Lura NG, Bjørneklett R, et al. Validation of two IgA nephropathy risk-prediction tools using a cohort with a long follow-up. Nephrol Dial Transplant. 2023. PMID: 35904322. doi:10.1093/ndt/gfac225
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。